Brokers Issue Forecasts for Pyxis Oncology FY2027 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at William Blair issued their FY2027 earnings estimates for Pyxis Oncology in a report released on Tuesday, November 4th. William Blair analyst A. Hsieh anticipates that the company will post earnings of ($1.55) per share for the year. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01.

Other equities research analysts have also recently issued research reports about the stock. Guggenheim upped their price objective on shares of Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Pyxis Oncology in a report on Tuesday, August 19th. Stifel Nicolaus began coverage on shares of Pyxis Oncology in a research note on Monday. They issued a “buy” rating and a $9.00 price target on the stock. Zacks Research cut shares of Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Finally, Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Friday, October 3rd. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.40.

Pyxis Oncology Price Performance

Shares of NASDAQ PYXS opened at $3.91 on Thursday. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $5.39. The company’s 50-day moving average is $2.62 and its 200 day moving average is $1.68. The stock has a market capitalization of $243.44 million, a P/E ratio of -2.44 and a beta of 1.41.

Institutional Investors Weigh In On Pyxis Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in PYXS. Bank of America Corp DE boosted its holdings in Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock worth $84,000 after purchasing an additional 9,062 shares during the last quarter. Pier 88 Investment Partners LLC raised its position in Pyxis Oncology by 296.6% in the first quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company’s stock worth $383,000 after acquiring an additional 292,370 shares during the period. Nuveen LLC bought a new position in Pyxis Oncology in the first quarter worth approximately $125,000. 683 Capital Management LLC raised its position in Pyxis Oncology by 32.5% in the first quarter. 683 Capital Management LLC now owns 550,000 shares of the company’s stock worth $539,000 after acquiring an additional 135,000 shares during the period. Finally, Acadian Asset Management LLC bought a new position in Pyxis Oncology in the first quarter worth approximately $81,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.